(Q28238985)

English

Ambrisentan

scientific article (publication date: August 2011)

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Ambrisentan (English)

0 references

author name string

James E Frampton

1

0 references

language of work or name

0 references

publication date

1 August 2011

0 references

American journal of cardiovascular drugs

0 references

11

0 references

4

0 references

215-26

0 references

Vascular endothelium summary statement V: Pulmonary hypertension and acute lung injury: public health implications

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Pulmonary hypertension: evaluation and management

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Drug treatment of pulmonary arterial hypertension: current and future agents

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Updated clinical classification of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Guidelines for the diagnosis and treatment of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Inflammation, growth factors, and pulmonary vascular remodeling

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Cellular and molecular basis of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Diagnosis and assessment of pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Targeted oral therapies in the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Ambrisentan for the management of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Tadalafil: in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Sildenafil: a review of its use in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Endothelin receptor antagonists in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Role of endothelin-1 in clinical hypertension: 20 years on.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Ambrisentan, a non-peptide endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

1 reference

https://api.crossref.org/works/10.2165%2F11207340-000000000-00000

21 January 2018

Identifiers

10.2165/11207340-000000000-00000

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28238985&oldid=2177528668"